CME Posttest: HIV and Cardiometabolic Abnormalities: New Perspectives and Treatment UpdateJAIDS Journal of Acquired Immune Deficiency Syndromes: September 1st, 2008 - Volume 49 - Issue - p S101 doi: 10.1097/QAI.0b013e3181865275 CME Free Article MetricsMetrics 1. Which statement best describes the lipid-related findings of the Multicenter AIDS Cohort Study (MACS) trial? a. Highly active antiretroviral therapy (HAART) caused a significant rise in total cholesterol and low-density lipoprotein cholesterol (LDL-C) compared with preinfection levels. b. Serum levels of total cholesterol, LDL-C, and high-density lipoprotein cholesterol (HDL-C) decreased upon infection with HIV. c. Serum levels of total cholesterol and LDL-C decreased upon initiation of HAART. d. Levels of HDL-C increased significantly upon initiation of HAART. e. Triglyceride levels were significantly elevated upon both infection and initiation of HAART. 2. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study of myocardial infarction (MI) risk found that: a. Patients demonstrated a high level of cardiovascular risk at baseline. b. A progressive increase in risk of MI was associated with increased length of antiretroviral therapy. c. Protease inhibitors demonstrated an increased risk for MI compared with nonnucleoside reverse transcriptase inhibitors. d. Increase in cardiovascular risk was related to concentrations of serum lipids. e. All of the above 3. Which of the following is not a risk factor for the development of type 2 diabetes? a. Older age b. Hypertension c. High levels of HDL-C and low levels of triglycerides d. Decreased physical activity e. Having a first-degree relative with diabetes 4. Which of the following statements concerning the management of diabetes in HIV-infected patients is false? a. The weight loss associated with metformin can improve HIV-related lipoatrophy. b. Losing weight and increasing physical activity are recommended as first-line therapy. c. Standards of care for diabetes are similar to those for non-HIV-infected patients. d. A 1.5% improvement of A1C levels is expected with metformin. e. Use of glitazones is generally not recommended for individuals with significant cardiovascular disease. 5. Which of the following interventions is not among those used to treat lipohypertrophy? a. Tesamorelin b. Weight loss c. Elimination of thymidine analogs d. Human growth hormone e. Metformin 6. Dietary supplementation with _________ can improve HIV-related lipoatrophy. a. Unsaturated fats b. Trans fats c. Cytosine d. Uridine e. Phenylalanine © 2008 Lippincott Williams & Wilkins, Inc.